These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 30267294

  • 21. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
    Olden KW, Chey WD, Shringarpure R, Paul Nicandro J, Chuang E, Earnest DL.
    Curr Med Res Opin; 2019 Mar; 35(3):461-472. PubMed ID: 30293448
    [Abstract] [Full Text] [Related]

  • 22. Eluxadoline: First Global Approval.
    Garnock-Jones KP.
    Drugs; 2015 Jul; 75(11):1305-10. PubMed ID: 26149369
    [Abstract] [Full Text] [Related]

  • 23. ▼ Eluxadoline for IBS-D.
    Drug Ther Bull; 2017 Aug; 55(8):90-93. PubMed ID: 28808081
    [Abstract] [Full Text] [Related]

  • 24. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea.
    Lacy BE, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Bellefleur R, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre AA.
    Adv Ther; 2024 Jun; 41(6):2253-2266. PubMed ID: 38619720
    [Abstract] [Full Text] [Related]

  • 25. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
    Brenner DM, Sayuk GS.
    Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
    [Abstract] [Full Text] [Related]

  • 26. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
    Nee J, Zakari M, Lembo AJ.
    Expert Opin Pharmacother; 2015 Jan; 16(18):2781-92. PubMed ID: 26558923
    [Abstract] [Full Text] [Related]

  • 27. Safety and Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome-Diarrhea With or Without Bile Acid Diarrhea: Open-Label Study.
    Vijayvargiya P, Breen-Lyles M, Nord SL, Maselli D, Busciglio I, Boinpally R, Muslin A, Carrothers TJ, Camilleri M.
    Dig Dis Sci; 2022 Aug; 67(8):3911-3921. PubMed ID: 35122592
    [Abstract] [Full Text] [Related]

  • 28. Τ Eluxadoline for IBS-D.
    Drug Ther Bull; 2017 Aug; 55(8):91-92. PubMed ID: 28808082
    [No Abstract] [Full Text] [Related]

  • 29. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
    Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, Nishida A, Haruma K.
    Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
    [Abstract] [Full Text] [Related]

  • 30. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.
    Vera I, Júdez FJ.
    Rev Esp Enferm Dig; 2017 Nov; 109(11):788-794. PubMed ID: 28747053
    [Abstract] [Full Text] [Related]

  • 31. New treatment options for irritable bowel syndrome with predominant diarrhea.
    Weber HC.
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
    [Abstract] [Full Text] [Related]

  • 32. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea.
    Buono JL, Carson RT, Flores NM.
    Health Qual Life Outcomes; 2017 Feb 14; 15(1):35. PubMed ID: 28196491
    [Abstract] [Full Text] [Related]

  • 33. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
    Jones J, Lembo A, Heidelbaugh J, Kuritzky L, Lacy B.
    Curr Med Res Opin; 2021 Apr 14; 37(4):567-578. PubMed ID: 33566707
    [Abstract] [Full Text] [Related]

  • 34. Intestinal symptoms and psychological factors jointly affect quality of life of patients with irritable bowel syndrome with diarrhea.
    Zhu L, Huang D, Shi L, Liang L, Xu T, Chang M, Chen W, Wu D, Zhang F, Fang X.
    Health Qual Life Outcomes; 2015 Apr 18; 13():49. PubMed ID: 25925746
    [Abstract] [Full Text] [Related]

  • 35. Advancements in drug development for diarrhea-predominant irritable bowel syndrome.
    Dothel G, Barbaro MR, Raschi E, Barbara G, De Ponti F.
    Expert Opin Investig Drugs; 2018 Mar 18; 27(3):251-263. PubMed ID: 29451407
    [Abstract] [Full Text] [Related]

  • 36. Therapeutic Effect of Chang'an I Recipe ( I ) on Irritable Bowel Syndrome with Diarrhea: A Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial.
    Tang XD, Lu B, Li ZH, Wei W, Meng LN, Li BS, Tang ZP, Gao R, Wang FY, Lu F, Bian LQ, Zhao YP, Wang P, Zhang YQ.
    Chin J Integr Med; 2018 Sep 18; 24(9):645-652. PubMed ID: 27487786
    [Abstract] [Full Text] [Related]

  • 37. Eluxadoline approved for irritable bowel syndrome with diarrhea.
    Traynor K.
    Am J Health Syst Pharm; 2015 Jul 01; 72(13):1078. PubMed ID: 26092951
    [No Abstract] [Full Text] [Related]

  • 38. Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
    Med Lett Drugs Ther; 2016 Jan 04; 58(1485):4-5. PubMed ID: 26714241
    [No Abstract] [Full Text] [Related]

  • 39. Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: a randomized double-blind clinical trial.
    Abbasnezhad A, Amani R, Hajiani E, Alavinejad P, Cheraghian B, Ghadiri A.
    Neurogastroenterol Motil; 2016 Oct 04; 28(10):1533-44. PubMed ID: 27154424
    [Abstract] [Full Text] [Related]

  • 40. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
    Gawron AJ, Bielefeldt K.
    Clin Gastroenterol Hepatol; 2018 Mar 04; 16(3):378-384.e2. PubMed ID: 28804032
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.